Summary
IDEXX Laboratories, Inc. reported solid financial results for the nine months ended September 30, 2012, with total revenue increasing by 6.8% to $973.8 million. The Companion Animal Group (CAG) remains the largest segment, driving growth with an 8.1% revenue increase year-over-year, primarily due to strong performance in reference laboratory diagnostics and consulting services, as well as rapid assay products. The company's financial position remains robust, with cash and cash equivalents increasing to $221.4 million and a healthy working capital of $154.9 million. Management expects these resources, along with its credit facility, to be sufficient to fund operations and strategic growth initiatives. The company is actively managing potential regulatory and legal challenges, notably the ongoing FTC investigation into its marketing and sales practices. IDEXX has taken proactive steps, including modifying an agreement with a key distributor, to address concerns and is negotiating a consent order. While the outcome remains uncertain, management believes these actions will mitigate material adverse effects on financial statements. The company continues to prioritize innovation and market expansion across its segments, including veterinary diagnostics, water quality, and livestock/poultry health, while navigating economic uncertainties and foreign currency fluctuations.
Financial Highlights
50 data points| Revenue | $315.48M |
| Cost of Revenue | $144.84M |
| Gross Profit | $170.63M |
| R&D Expenses | $20.35M |
| Operating Income | $62.91M |
| Interest Expense | $873K |
| Net Income | $42.85M |
| EPS (Basic) | $0.39 |
| EPS (Diluted) | $0.38 |
| Shares Outstanding (Basic) | 109.88M |
| Shares Outstanding (Diluted) | 112.18M |
Key Highlights
- 1Total revenue for the nine months ended September 30, 2012, increased by 6.8% to $973.8 million, compared to $911.5 million in the prior year period.
- 2The Companion Animal Group (CAG) continues to be the primary revenue driver, with an 8.1% increase in revenue year-over-year, reaching $808.7 million for the nine months.
- 3Net income attributable to IDEXX Laboratories, Inc. stockholders rose to $134.9 million for the nine months ended September 30, 2012, up from $123.8 million in the prior year.
- 4Diluted earnings per share increased to $2.40 for the nine months ended September 30, 2012, from $2.11 in the comparable prior year period.
- 5Cash and cash equivalents increased to $221.4 million at September 30, 2012, from $183.9 million at December 31, 2011, indicating strong liquidity.
- 6The company reported $153.5 million in cash flow from operating activities for the nine months ended September 30, 2012, slightly down from $163.5 million in the prior year, reflecting changes in working capital.
- 7IDEXX is actively engaged in discussions and negotiations with the FTC regarding an investigation into its marketing and sales practices, with efforts underway to reach a resolution.